CSPC Ouyi Pharmaceutical Co., Ltd. $1093.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS10
PHASE 3 / 2-35
RECRUITING1
READOUTS ≤12 MONTHS5
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SYHX2011 NCT06354114 |
P2 | Not yet recruiting | Advanced Breast Cancer | 80 | 2024-10-31 |
| Dextromethorphan and Bupropion Sustained-Release Tablets NCT06958692 |
P3 | Recruiting | Major Depressive Disorder (MDD) | 388 | 2026-09-30 |
| NCT07026968 NCT07026968 |
P3 | Active, not recruiting | Type 2 Diabetes | 815 | 2026-10-30 |
| SYHX1901 NCT06943950 |
P3 | Not yet recruiting | Moderate to Severe Plaque Psoriasis | 500 | 2027-04-28 |
| SYHX1901 NCT06562894 |
P2 | Not yet recruiting | Severe Alopecia Areata | 156 | 2027-05-31 (+17 mo) |
| Bempedoic Acid Tablet NCT07623915 |
P3 | Not yet recruiting | Primary Hyperlipidemia | 222 | 2027-06-30 |
| SYH2069 Injection (group 1) NCT07796477 |
P2 | Not yet recruiting | T2DM (Type 2 Diabetes Mellitus) | 240 | 2027-09-28 |
| SYH2069 Injection NCT07803991 |
P2 | Not yet recruiting | Overweight or Obesity | 360 | 2027-09-30 |
| SYH2066 NCT07881991 |
P2 | Not yet recruiting | Respiratory Syncytial Virus Infections | 80 | 2027-12-31 |
| Liposomal Irinotecan NCT06571461 |
P3 | Not yet recruiting | Pancreatic Cancer | 408 | 2028-01 |